| Pharmaceutical liability refers to legal theories and | | | | controls used to maintain the drug's quality are |
| ways to prove that the manufacturer of a | | | | adequate to preserve the drug's identity, strength, |
| prescription drug, over-the-counter medication, | | | | quality, and purity. |
| dietary supplement or herbal remedy may be | | | | The NDA documents the drug's history including what |
| responsible when the drug causes injury or death. | | | | happened during the clinical tests, what the |
| The Food and Drug Administration ("FDA") is the | | | | ingredients of the drug are, the results of the animal |
| government agency that is responsible for ensuring | | | | studies, how the drug behaves in the body, and how |
| that our drug supply is safe and effective. Approval | | | | it is manufactured, processed and packaged. After |
| of prescription drugs is the job of the FDA's Center | | | | the FDA approves a drug for a particular use, |
| for Drug Evaluation and Research ("CDER"). | | | | patients who are injured by the drug must look to |
| Since 1938, every new drug has been the subject of | | | | the manufacturer for redress, whether the drug is |
| an approved New Drug Application ("NDA") before | | | | used for its approved purpose or for some other |
| U.S. commercialization. The NDA is the mechanism by | | | | reason (known as "off-label" use). Manufacturers will |
| which drug sponsors formally propose to the FDA | | | | sometimes try to persuade a jury that, because the |
| that the FDA approve a new pharmaceutical for sale | | | | FDA approved the medication, the manufacturer |
| and marketing in the U.S. The data gathered during | | | | should not be liable for any injuries the medication |
| the animal studies and human clinical trials of an | | | | caused, particularly in cases of "off-label" use. |
| Investigational New Drug become part of the NDA. | | | | In some instances, a company discovers that one of |
| The FDA reviews the medication and may approve it | | | | its products is defective and has the potential to |
| for sale, but the FDA does not guarantee drug | | | | cause injury, pain or death. The company may recall |
| safety. | | | | the drug entirely on its own. In others instances, the |
| The purpose of the NDA is to provide enough | | | | FDA informs a company of findings that one of its |
| information to permit the FDA reviewer to reach the | | | | products is defective and suggests or requests a |
| following key decisions:o Whether the drug is safe | | | | recall. Usually, the company will comply. If the firm |
| and effective in its proposed use(s), and whether the | | | | does not recall the product, then FDA can seek legal |
| benefits of the drug outweigh the risks.o Whether | | | | action. FDA actions may include seizure of the |
| the drug's proposed labeling or package insert is | | | | available drug, and/or an injunction against the firm, |
| appropriate, and what it should contain.o Whether the | | | | and a court order for recall of the product. |
| methods used to manufacture the drug and the | | | | |